NCT06982521: An ongoing trial by Relay Therapeutics, Inc.
This trial is ongoing. It must report results 3 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06982521 |
|---|---|
| Title | A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 26, 2025 |
| Completion date | April 30, 2028 |
| Required reporting date | April 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |